Buoyed By T-DM1 EMILIA Data, Roche Leaps To Early Breast Cancer Trial

In Phase III EMILIA study, Herceptin-containing antibody drug conjugate demonstrates three-month progression-free survival benefit, trend toward overall survival and, importantly, better safety profile. Results pave way for new trials in earlier disease using new FDA approval pathway.